Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px

Document › Details

Teva Pharmaceutical Industries Ltd.. (8/3/17). "Press Relase: Teva Reports Second Quarter 2017 Financial Results". Jerusalem.

	Organisation	Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)
	Group	Teva (Group)
	Organisation 2	Celltrion Inc. (KRX: 068270)
	Group	Celltrion (Group)
	Product	Copaxone®
	Product 2	pharmaceutical
	Person	Peterburg, Yitzhak (Teva 201702– Interim CEO)

Original document
accessed by [iito] on 2017-08-04

Record changed: 2023-06-05

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Teva (Group)

[1] Rentschler Biopharma SE. (11/16/22). "Press Release: Rentschler Biopharma Appoints Christiane Bardroff as Chief Operating Officer and Member of the Executive Board". Laupheim....
[2] Oxford Biomedica plc. (7/15/21). "Press Release: Oxford Biomedica Appoints Dr. Michael Hayden as Non-Executive Director". Oxford....
[3] Almirall S.A.. (2/3/21). "Press Release: Almirall Announces Gianfranco Nazzi as New CEO"....
[4] Teva Pharmaceutical Industries Ltd.. (11/7/19). "Press Release: Teva Announces Appointment of New Chief Financial Officer". Jerusalem....
[5] BiomX Ltd.. (10/15/19). "Press Release: BiomX Appoints Merav Bassan as Chief Development Officer". Ness Ziona....
[6] Foundation Medicine, Inc.. (1/7/19). "Press Release: Foundation Medicine Announces Executive Leadership Transition". Cambridge, MA....
[7] Teva Pharmaceutical Industries Ltd.. (6/15/18). "Press Release: Teva Provides Update on Clinical Trial of Fremanezumab for Use in Chronic Cluster Headache". Jerusalem....
[8] Teva Pharmaceutical Industries Ltd.. (11/27/17). "Press Release: Teva Announces New Organization Structure and Leadership Changes". Jerusalem....
[9] Teva Pharmaceutical Industries Ltd.. (7/31/17). "Press Relase: Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Herceptin (trastuzumab)". Incheon & Jerusalem....
[10] Teva Pharmaceutical Industries Ltd.. (6/29/17). "Press Release: Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Rituxan (rituximab)". Incheon & Jerusalem....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]